Through the Maryland Innovation Initiative and MSCRF, Life Sprout has been able to forge into clinical trials with their synthetic tissue composites.

Soft tissue losses from cancer surgery, trauma, and aging are a ubiquitous problem in clinical medicine, affecting millions of patients per year. 

LifeSprout’s first-in-class synthetic, nanofiber-hydrogel composites are formulated to feel like native soft tissues while maintaining an open, porous structure. The team’s preclinical studies demonstrate excellent tissue compatibility and superior tissue integration by permitting host tissue ingrowth. The company was founded in 2015 by leading scientists and surgeons at Johns Hopkins University with the goal of developing the next-generation of synthetic soft tissue substitutes for aesthetic and reconstructive medicine.

Leadership Overview

Co-Founder and CTO: David Zachary Martin, MD
Co-Founder and CEO: Aimee Purcell Martin

Products/Services

LifeSprout’s first-in-class synthetic, nanofiber-hydrogel composites are formulated to feel like native soft tissues while maintaining an open, porous structure.

For more information, visit https://www.lifesproutbio.com